EUCTR2004-004088-31-ES进行中（未招募）1 期
A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 weeks in Newly Diagnosed Children and Adolescents Outpatients with Attention-Deficit/Hyperactivity Disorder
illy S.A.0 个研究点目标入组 151 人开始时间: 2012年6月11日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 151
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1]Child or adolescent patients must be at least 6 years of age, but must not yet have reached their 16th birthday prior to Visit 1, when informed consent is obtained.
- •[2]Patients must meet the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition Text Revision? (DSM-IV-TR?) diagnostic criteria for ADHD. For the purposes of this study the diagnosis of ADHD will be confirmed during Visit 1 by administering the K-SADS-PL. Patients must also have an ADHDRS-IV-Parent:Inv score at least 1.5 standard deviations above the age norm for their diagnostic subtype at both Visit 1 and Visit 2. In addition, they must have a CGI-ADHD-S score ³4 at both Visit 1 and Visit 2.
- •[3]Patients must have a newly diagnosed case of ADHD. Newly diagnosed case of ADHD means that a specialist (including pediatrician, child psychiatrist, or child neurologist) or child psychologist has diagnosed ADHD (according DSM?IV-TR or International Statistical Classification of Diseases and Related Health Problems [World Health Organisation; 10th Revision] [ICD 10] criteria) within 3 months prior to Visit 1.
- •[4]Patients must be drug naive before Visit 1. Drug naive is defined as having not received more than two consecutive days of any dose of stimulants or more than 6 days consecutive of any pharmacological treatment for ADHD during the patient?s lifetime and having not received any dose of stimulant or more than 1 day on any pharmacological treatment for ADHD within 30 days before Visit 1.
- •[5]Patients must have an electrocardiogram (ECG) at Visit 1 with results available and reviewed prior to dispensing drug at Visit 2. If an ECG shows an abnormality meeting one or more of the criteria in Protocol Attachment LYDM.3, the patient must be excluded from the study. Patients with other abnormalities may be included at the discretion of the investigator; however, the Lilly physician monitor or designee must be notified.
- •[6]Patients must have laboratory results, including serum chemistries, hematology, and urinalysis showing no significant abnormalities (significant would include laboratory deviations requiring acute medical intervention or further medical evaluation) and no clinical information that, in the judgment of a physician, should preclude a patient?s participation at study entry. A patient with a significant abnormal laboratory result may enter the study if, after appropriate medical evaluation, the result does not indicate a serious medical condition that in the investigator?s judgment would preclude participation. If there is any question about the appropriateness of participation or relevance of a particular finding, the Lilly physician monitoring the study should be consulted.
- •[7]Patients must be able to swallow capsules.
- •[8]Patients must be of normal intelligence as assessed by the investigator (that is, without a general impairment of intelligence and likely, in the investigator?s judgment, to achieve a score of ³70 on an IQ test). The administration of a formal IQ test is not an entry requirement for this study. Specific learning disabilities are not considered general impairments of intelligence.
- •[9]Patients and parents have been judged by the investigator to be reliable to keep appointments for clinic visits and all tests and examinations required by the protocol.
- •[10]Patients and parents must be able to communicate effectively with the investigator and site personnel.
- •Are the trial subjects under 18? yes
- •Number of subjects fo
排除标准
- •[11]Patients with history of ADHD diagnosis longer than 3 months prior to Visit 1. Diagnosis of ADHD means that a specialist (including pediatrician, child psychiatrist, or child neurologist) or child psychologist has diagnosed ADHD (according DSM-IV-TR or ICD 10 criteria) and has registered it in medical records or verbally informed parents about this diagnosis.
- •[12]Patients who weigh less than 20 kg at study entry (Visit 1). If a patient?s weight changes after Visit 1 to a value outside of the stated range, the patient will still be eligible, and the weight should be rounded to the nearest value within the above range for dosing purposes.
- •[13]Patients who have a history of bipolar disorder (I or II), psychosis, or pervasive developmental disorder, or comorbid with any mood disorders. If the investigator believes that such a diagnosis has previously been made in error, he/she should contact the Lilly and discuss the case history with the Lilly physician responsible for the study prior to allowing the patient to enter the study
- •[14]Patients with a history of any seizure disorder (other than febrile seizures) or patients who are currently taking anticonvulsants for seizure control.
- •[15]Patients determined by the investigator to be at serious suicidal risk.
- •[16]Patients with a history of severe allergies to more than one class of medications or multiple adverse drug reactions.
- •[17]Patients with a history of alcohol or drug abuse within the past 3 months (excessive or compulsive use as judged by the investigator) or who are currently using alcohol, drugs of abuse, or any prescribed or over-the-counter medication in a manner that the investigator considers indicative of abuse.
- •[18]Patients with cardiovascular disease or other conditions that could be aggravated by an increased heart rate or increased blood pressure.
- •[19]Patients who have a medical condition that would increase sympathetic nervous system activity markedly (for example, catecholamine-secreting neural tumor) or who are taking a medication on a daily basis that has sympathomimetic activity. Such medications can be taken on an as-needed basis.
- •[20]Patients who in the investigator?s judgment are likely to need psychotropic medications apart from the drugs under study, including health-food supplements that in the investigator?s opinion have central nervous system activity (for example, St. John?s Wort, melatonin).
- •[21]Patients who at any time during the study are likely to begin a structured psychotherapy aimed at ADHD. Psychotherapy initiated at least 1 month prior to study participation is acceptable; however, after study participation has begun only supportive or educational therapy is permitted.
- •[22]Patients who have used a monoamine oxidase inhibitor (MAOI) during the 2 weeks (14 days) prior to Visit 2.
- •[23]Patients with history of glaucoma.
- •[24]Patients with hypertension.
- •[25]Female patients who are pregnant or who are breast-feeding. Sexually active females must use a medically acceptable method of contraception. For this study, medically acceptable means of contraception include barrier methods (condom or diaphragm combined with spermicidal agent) or oral contraception. The rhythm method (abstinence during predicted times of ovulation with unprotected intercourse at other times) or coitus interruptus prior to ejaculation by the male partner are not acceptable means of contraception for this study if used in the absence of medically acceptable
研究者
相似试验
招募中
3 期
A study in subjects with Symptomatic genetic heart disease comparing sponsors drug Mavacamten with dummy drug.CTRI/2023/10/058870MyoKardia, Inc.
尚未招募
不适用
Clinical trial of hair vitamin gummies to improve hair and nail healthCTRI/2023/03/050199Mosaic Wellness Pvt Ltd
进行中（未招募）
1 期
A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline PhosphataseMedDRA version: 21.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871Primary Biliary CholangitisEUCTR2016-004599-23-ITGENKYOTEX SA111
进行中（未招募）
1 期
A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline PhosphatasePrimary Biliary CholangitisEUCTR2016-004599-23-GBGenkyotex SA102
进行中（未招募）
1 期
A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline PhosphataseMedDRA version: 20.0 Level: LLT Classification code 10036680 Term: Primary biliary cirrhosis System Organ Class: 100000023866Primary Biliary CholangitisEUCTR2016-004599-23-GRGenkyotex SA102